CD59 Deficiency Is Critical for C3 Binding on Red Blood Cells of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) during Anti-C5 Treatment (eculizumab)

Sica MIchela; Rondelli Tommaso; Ricci Patrizia; De Angioletti Maria; Risitano Antonio M.; Notaro Rosario

首页> 外文期刊>Blood: The Journal of the American Society of Hematology >CD59 Deficiency Is Critical for C3 Binding on Red Blood Cells of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) during Anti-C5 Treatment (eculizumab)

【24h】

CD59 Deficiency Is Critical for C3 Binding on Red Blood Cells of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) during Anti-C5 Treatment (eculizumab)

机译：CD59缺乏对抗C5治疗期间阵发性夜间血红蛋白（PNH）患者红细胞的C3结合至关重要

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology 》 |2016年第22期| 共6页
作者
Sica MIchela; Rondelli Tommaso; Ricci Patrizia; De Angioletti Maria; Risitano Antonio M.; Notaro Rosario;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病 ;
关键词

相似文献

外文文献
中文文献
专利

1. CD59 Deficiency Is Critical for C3 Binding on Red Blood Cells of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) during Anti-C5 Treatment (eculizumab) [J] . Sica MIchela, Rondelli Tommaso, Ricci Patrizia, Blood: The Journal of the American Society of Hematology . 2016 ,第22期

机译：CD59缺乏对抗C5治疗期间阵发性夜间血红蛋白（PNH）患者红细胞的C3结合至关重要
2. Effectiveness of eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) with or without aplastic anemia in the International PNH Registry [J] . Lee Jong Wook, de Latour Regis Peffault, Brodsky Robert A., American Journal of Hematology . 2019 ,第1期

机译：泌尿病患者患者的疗效患者（PNH），在国际PNH注册表中有或没有增强性贫血患者的患者
3. Topline-Results indicate the Success of the two Phase-3-ALXN1210 Clinical Trials in Complement Inhibitor Treatment-Naive Patients with paroxysmal nocturnal Hemoglobinuria (PNH) and those previously treated with Soliris (R) (Eculizumab) [J] . Transfusion medicine and hemotherapy: offizielles Organ der Deutschen Gesellschaft fur? Transfusionsmedizin und Immunham?atologie . 2018 ,第4期

机译：Topline-结果表明，两相3-ALXN1210临床试验中的补体抑制剂治疗 - 天真患者的临床试验，患有索昔肠杆菌（PNH）和先前用Soliris（r）（ar）（eculizumab）治疗的患者
4. HEMOPOIETIC STEM CELL TRANSPLANTATION (HSCT) FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) and ACQUIRED SEVERE APLASTIC ANEMtA (SAA):a report from the SAA Working Party of the European Blood and Marrow Transplant group (EBMT) [C] . Andrea Bacigalupo, Rosi Oneto, Barbara Bruno, International Symposium on PNH and Related Disorders . 2003

机译：血液发作干细胞移植（HSCT）用于阵发性夜间血红蛋白（PNH）和获得的严重Aplastic Anemta（SAA）：来自欧洲血液和骨髓移植组的SAA工作组（EBMT）的报告
5. Using Induced Pluripotent Stem Cells Derived from Patient Blood Samples for Transcriptional Modeling and the Evaluation of IGF-1 Treatment in Phelan-McDermid Syndrome [D] . Browne, Andrew 2018

机译：使用源自患者血液样本的诱导多能干细胞进行转录建模和IGF-1治疗在Phelan-McDermid综合征中的评价
6. Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody. [O] . W F Rosse, J V Dacie 1966

机译：正常人和阵发性夜间血红蛋白尿（PNH）红细胞的免疫裂解。 I. PNH红细胞对补体和特异性抗体裂解的敏感性。
7. Analysis of PI (phosphatidylinositol)-anchoring antigens in a patient of paroxysmal nocturnal hemoglobinuria (PNH) reveals deficiency of 1F5 antigen (CD59), a new complement-regulatory factor [O] . Taguchi Ryo, Funahashi Yasuhiro, Ikezawa Hiroh, 1990

机译：对阵发性夜间血红蛋白尿症（PNH）患者的PI（磷脂酰肌醇）锚定抗原进行分析，发现缺乏一种新的补体调节因子1F5抗原（CD59）。

CD59 Deficiency Is Critical for C3 Binding on Red Blood Cells of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) during Anti-C5 Treatment (eculizumab)

著录项

相似文献

相关主题

期刊订阅